Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients

ObjectiveLinc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological com...

Full description

Bibliographic Details
Main Authors: Huijuan Dai, Xiaonan Sheng, Rui Sha, Jing Peng, Fan Yang, Liheng Zhou, Yanping Lin, Yaqian Xu, Shan Zhang, Wenjin Yin, Jinsong Lu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.604319/full
id doaj-7d7690f68d084718967e519f9a3647a4
record_format Article
spelling doaj-7d7690f68d084718967e519f9a3647a42021-03-02T08:01:17ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.604319604319Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer PatientsHuijuan DaiXiaonan ShengRui ShaJing PengFan YangLiheng ZhouYanping LinYaqian XuShan ZhangWenjin YinJinsong LuObjectiveLinc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological complete response (pCR) in breast cancer patients.Materials and MethodsThe present study examined the predictive role of Linc00665 expression in pCR after NAC using both univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to evaluate the performance of Linc00665 in predicting pCR. The Kyoto Encyclopedia of Gene and Genome (KEGG) analysis and Gene Set Enrichment Analysis (GSEA) were also conducted to determine the biological processes where Linc00665 may participate in.ResultsThe present study study totally enrolled 102 breast cancer patients. The univariate analysis showed that Linc00665 level, human epidermal growth factor receptor 2 (HER2) status and hormone receptor (HR) status were correlated with pCR. The multivariate analysis showed that Linc00665 expression was an independent predictor of pCR (OR = 0.351, 95% CI: 0.125–0.936, P = 0.040), especially in patients with HR-positive/HER2-negative subtype (OR = 0.272, 95% CI: 0.104–0.664, P = 0.005). The KEGG analysis indicated that Linc00665 may be involved in drug metabolism. The GSEA analysis revealed that Linc00665 is correlated to DNA damage repair.ConclusionLinc00665 may be a potential novel predictive biomarker for breast cancer in NAC, especially for HR-positive/HER2-negative patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.604319/fullbreast cancerlong non-coding RNAneoadjuvant chemotherapypredictive biomarkerpathological complete response
collection DOAJ
language English
format Article
sources DOAJ
author Huijuan Dai
Xiaonan Sheng
Rui Sha
Jing Peng
Fan Yang
Liheng Zhou
Yanping Lin
Yaqian Xu
Shan Zhang
Wenjin Yin
Jinsong Lu
spellingShingle Huijuan Dai
Xiaonan Sheng
Rui Sha
Jing Peng
Fan Yang
Liheng Zhou
Yanping Lin
Yaqian Xu
Shan Zhang
Wenjin Yin
Jinsong Lu
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
Frontiers in Oncology
breast cancer
long non-coding RNA
neoadjuvant chemotherapy
predictive biomarker
pathological complete response
author_facet Huijuan Dai
Xiaonan Sheng
Rui Sha
Jing Peng
Fan Yang
Liheng Zhou
Yanping Lin
Yaqian Xu
Shan Zhang
Wenjin Yin
Jinsong Lu
author_sort Huijuan Dai
title Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_short Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_full Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_fullStr Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_full_unstemmed Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients
title_sort linc00665 can predict the response to cisplatin-paclitaxel neoadjuvant chemotherapy for breast cancer patients
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-03-01
description ObjectiveLinc00665 is a novel long non-coding RNA that can promote the progression of breast cancer, but its value in predicting the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer has not been reported. We aim to analyze the correlation between Linc00665 expression and pathological complete response (pCR) in breast cancer patients.Materials and MethodsThe present study examined the predictive role of Linc00665 expression in pCR after NAC using both univariate and multivariate logistic regression analyses. Receiver operating characteristic (ROC) curve and area under curve (AUC) were utilized to evaluate the performance of Linc00665 in predicting pCR. The Kyoto Encyclopedia of Gene and Genome (KEGG) analysis and Gene Set Enrichment Analysis (GSEA) were also conducted to determine the biological processes where Linc00665 may participate in.ResultsThe present study study totally enrolled 102 breast cancer patients. The univariate analysis showed that Linc00665 level, human epidermal growth factor receptor 2 (HER2) status and hormone receptor (HR) status were correlated with pCR. The multivariate analysis showed that Linc00665 expression was an independent predictor of pCR (OR = 0.351, 95% CI: 0.125–0.936, P = 0.040), especially in patients with HR-positive/HER2-negative subtype (OR = 0.272, 95% CI: 0.104–0.664, P = 0.005). The KEGG analysis indicated that Linc00665 may be involved in drug metabolism. The GSEA analysis revealed that Linc00665 is correlated to DNA damage repair.ConclusionLinc00665 may be a potential novel predictive biomarker for breast cancer in NAC, especially for HR-positive/HER2-negative patients.
topic breast cancer
long non-coding RNA
neoadjuvant chemotherapy
predictive biomarker
pathological complete response
url https://www.frontiersin.org/articles/10.3389/fonc.2021.604319/full
work_keys_str_mv AT huijuandai linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT xiaonansheng linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT ruisha linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT jingpeng linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT fanyang linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT lihengzhou linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT yanpinglin linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT yaqianxu linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT shanzhang linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT wenjinyin linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
AT jinsonglu linc00665canpredicttheresponsetocisplatinpaclitaxelneoadjuvantchemotherapyforbreastcancerpatients
_version_ 1724240847905488896